About Capivasertib API
Therapeutic CategoryOncology
CAS Number
1143532‑39‑1
API Technology
Small‑molecule synthetic API
Dose Form
Tablets
Dr Reddy's Development Status
Under Development
Mechanism of action
Capivasertib inhibits all three AKT isoforms (AKT1, AKT2, AKT3).
AKT is a central signaling node in the PI3K/AKT/mTOR pathway, regulating cell proliferation, survival, and metabolism.
By blocking AKT kinase activity, capivasertib:
Inhibits phosphorylation of downstream AKT substrates
Suppresses tumor cell growth and survival
Overcomes resistance to endocrine therapy driven by PIK3CA mutations, AKT1 mutations, or PTEN loss
Demonstrates antitumor activity both as monotherapy and in combination with endocrine agents.
Indication
"Approved indication (FDA):
In combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)‑positive, HER2‑negative, locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN alterations, following disease progression on endocrine therapy."
Related APIs
Capivasertib
Oncology
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.